Evaluation of the bactericidal activity of temafloxacin
- PMID: 1662893
- DOI: 10.1016/0002-9343(91)90307-j
Evaluation of the bactericidal activity of temafloxacin
Abstract
Although the fluoroquinolones share many properties, these agents differ in their ability to kill the same bacterial strain. The bactericidal activity of temafloxacin against a number of pathogens has been compared with that of other fluoroquinolones by determination of minimal bactericidal concentration, time-kill kinetics, and postantibiotic effect. Studies have demonstrated that temafloxacin has equivalent or superior ability to kill when compared with other fluoroquinolones. Temafloxacin, ciprofloxacin, and PD 117558 were more active than other fluoroquinolones against Mycobacterium avium complex, with 90% minimal bactericidal concentrations (MBC90S; 8-16 micrograms/mL) four- to eightfold greater than 90% minimal inhibitory concentrations (MIC90S; 2 micrograms/mL). Against Chlamydia trachomatis the MIC90 and MBC90 of temafloxacin were both 0.25 microgram/mL; ciprofloxacin was less active (MBC90 twice the MIC90), and norfloxacin was least active. Temafloxacin demonstrated more rapid killing kinetics than did ciprofloxacin or ofloxacin at all concentrations tested against Streptococcus pyogenes. Findings were similar against Streptococcus pneumoniae at antibiotic concentrations of 1-2 micrograms/mL. Similar time-kill curves against Escherichia coli were observed for temafloxacin, ciprofloxacin, and difloxacin. Time-kill kinetics of temafloxacin against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) were superior to those of ciprofloxacin and ofloxacin. Postantibiotic effect with temafloxacin against Legionella pneumophila showed a considerable delay in regrowth, and temafloxacin delayed regrowth of MRSA and MSSA to a greater extent than did ciprofloxacin or ofloxacin. By the three methods used in the studies to assess bactericidal activity that are currently published, temafloxacin had equivalent or superior activity to the comparative fluoroquinolones tested. Other organisms remain to be tested and the significance of these findings determined in clinical studies.
Similar articles
-
In-vitro activity of temafloxacin for gram-positive pathogens.J Antimicrob Chemother. 1991 Dec;28 Suppl C:9-14. doi: 10.1093/jac/28.suppl_c.9. J Antimicrob Chemother. 1991. PMID: 1664835
-
In vitro activity of temafloxacin against gram-negative bacteria: an overview.Am J Med. 1991 Dec 30;91(6A):19S-23S. doi: 10.1016/0002-9343(91)90304-g. Am J Med. 1991. PMID: 1662890
-
Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.Am J Med. 1991 Dec 30;91(6A):12S-14S. doi: 10.1016/0002-9343(91)90302-e. Am J Med. 1991. PMID: 1662881
-
Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.Am J Med. 1991 Dec 30;91(6A):93S-100S. doi: 10.1016/0002-9343(91)90318-r. Am J Med. 1991. PMID: 1662900 Review.
-
Temafloxacin: an overview.Am J Med. 1991 Dec 30;91(6A):166S-172S. doi: 10.1016/0002-9343(91)90332-r. Am J Med. 1991. PMID: 1662889 Review.
Cited by
-
Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.Environ Sci Pollut Res Int. 2011 Aug;19(7):2697-707. doi: 10.1007/s11356-012-0766-7. Epub 2012 Feb 4. Environ Sci Pollut Res Int. 2011. PMID: 22307896
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources